UNSPSC 51372010: Ketorfanol

This classification denotes an opioid with the molecular formula C20H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Z0ZXE70XL, chemically known as morphinan-6-one, 17-(cyclopropylmethyl)-4-hydroxy-; but generally known as ketorfanol, which bears US NIH Compound Identifier 5490677. European Medicines Agency schedules Ketorfanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08375MIG.

UNSPSC 51372010 Ketorfanol, a Commodity code, does not reflect the pharmaceutical procurement activity actually appearing in recent state and local solicitations tagged under it. The three most recent opportunities show purchasing of naloxone, generic pharmaceuticals, and over-the-counter products — none of which is ketorfanol. State and local governments buying under this code are acquiring emergency opioid-reversal medications (naloxone), generic multi-source pharmaceuticals through cooperative purchasing arrangements, and drug deactivation systems to support public health and community health initiatives, not the specific analgesic ketorfanol. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing alliances administered by state procurement offices (Minnesota Department of Administration's Office of State Procurement / MMCAP).

Recent solicitations span Florida, Texas, and Minnesota through a cooperative purchasing vehicle. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries due by July 26, 2023 (note: the due date appears to be a data error in the source). The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit managers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The code shows minimal recent activity aligned to its nominal scope and appears to be misapplied to broader pharmaceutical procurement categories.